Salzman et al., 2025 - Google Patents
Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and MyelofibrosisSalzman et al., 2025
- Document ID
- 11231075990873907927
- Author
- Salzman G
- Mullally A
- Publication year
- Publication venue
- Blood
External Links
Snippet
The discovery of calreticulin (CALR) mutations in patients with myeloproliferative neoplasms (MPN) has paved the way for the elucidation of a unique disease mechanism that is particularly well-suited to targeting by biologics. All MPN-associated pathogenic CALR …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7316421B2 (en) | Glycan-interacting compounds and methods of use | |
| JP7678753B2 (en) | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1 (ROR1) | |
| US20210040206A1 (en) | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies | |
| CN115087488A (en) | Antibodies and fusion proteins binding to CCR8 and uses thereof | |
| KR20220016945A (en) | multispecific protein | |
| DK2547359T3 (en) | Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS | |
| JP2018508483A (en) | Treatment of cancer with anti-LAP monoclonal antibodies | |
| JP7593939B2 (en) | Anti-MERTK antibodies and methods of use thereof | |
| US20230181642A1 (en) | Immune cells with enhanced function | |
| JP2021054825A (en) | Xbp1 peptide, cd138 peptide, and cs1 peptide | |
| CN115768786A (en) | multispecific protein | |
| Gillissen et al. | AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses | |
| JP2023541996A (en) | Clinical administration of SIRP1α chimeric protein | |
| US20210070845A1 (en) | Anti-cct5 binding molecules and methods of use thereof | |
| CN104995207B (en) | Inhibitors of β integrin-G protein α subunit binding interactions | |
| Salzman et al. | Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and Myelofibrosis | |
| JP2021518348A (en) | Combined with medicine | |
| CN116323662A (en) | Anti-ABCG2 antibodies and uses thereof | |
| WO2022236134A1 (en) | Anti-il-27 antibodies and uses thereof | |
| Wang et al. | Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles | |
| Wang | Engineering receptor-based decoys for the treatment of cancer using a yeast surface display platform | |
| WO2025226603A1 (en) | Methods for treating cancer using anti-ccr8 antibodies | |
| Jalil | The Development Of Multivalent Nano-Self Peptides As Antagonists For Antibody-Dependent Macrophage Phagocytosis | |
| HK40098919A (en) | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine | |
| KR20230147078A (en) | T cells for use in therapy |